IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for determining a bortezomib therapy regimen for treating a liquid tumor in a patient comprising:

a) selecting features from the Predictive Markers in Table 1 to select a predictive marker set;

b) selecting a means for measuring the level of expression of the features in the predictive marker set;

c) isolating a liquid tumor sample from the patient;

d) ~~determining~~ measuring the level of expression of the features ~~in~~ of the predictive marker set in the liquid tumor sample to determine whether there are significant expression levels of the features; ~~and~~

[[c]] e) determining a bortezomib regimen for treating the tumor based on ~~the expression of the features in the predictive marker set, wherein a~~ whether the significant expression ~~level is~~ levels are indicative that the patient is either a responsive patient or a non-responsive patient, wherein indication of responsiveness determines that the patient can benefit from bortezomib therapy.

2. (Currently Amended) The method of claim 1 wherein the means for measuring the level of expression of the features in the predictive marker set is ~~determined by detection of~~ detecting the mRNA of the feature.

3. Canceled

4. (Previously Presented) The method of claim 1 wherein the features in the predictive marker set are selected from at least one of the markers identified in Table 1as having a rank under 100.

5. (Original) The method of claim 1 wherein determining the significant level of expression is determined by comparison with a control marker or by comparison to a predetermined standard.

6. Canceled

7. (Original) The method of claim 1 wherein the liquid tumor is selected from the group consisting of myelomas, multiple myeloma, Non-Hodgkins Lymphoma, B-cell lymphomas, Waldenstrom's syndrome, chronic lymphocytic leukemia, and other leukemias.

8. Canceled

9. Canceled

10. (Original) The method of claim 1, wherein the patient sample comprising tumor cells is obtained from the subject any time selected from prior to tumor therapy, concurrently with tumor therapy or after tumor therapy.

11. – 28. Canceled

29. (Previously Presented) The method of claim 1, wherein the predictive marker set is selected by the Signal-to-Noise Ratio method.

30. (Withdrawn) The method of claim 1, wherein the predictive marker set is selected by the Class-Based Threshold method.

31. (Previously Presented) The method of claim 1, wherein the predictive marker set identifies a responsive patient.

32. (Previously Presented) The method of claim 1, wherein the predictive marker set identifies a non-responsive patient.

33. (Previously Presented) The method of claim 1, wherein the method selects a predictive marker set selected from the group consisting of Table 4, Table 5 and Table 6.

34. – 41. Canceled

42. (Previously Presented) The method of claim 1, wherein the predictive marker set comprises Predictive Marker No. 149.

43. (New) The method of claim 1, where the means for measuring the level of expression of the features is contacting the sample with a probe array.